Related Experiment Videos
Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma
American Journal of Clinical Oncology
|June 1, 1987
Summary
Aclacinomycin A (ACLA-A) showed limited efficacy in treating advanced lung cancer. Severe myelosuppression led to dose reduction, and no complete or partial responses were observed in this Phase II trial.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bronchogenic squamous-cell carcinoma is a significant cause of cancer mortality.
- Aclacinomycin A (ACLA-A) is an anthracycline antibiotic with potential antineoplastic properties.
Purpose of the Study:
- To evaluate the therapeutic efficacy and toxicity of Aclacinomycin A (ACLA-A) in patients with advanced bronchogenic squamous-cell carcinoma.
Main Methods:
- A Phase II clinical trial was conducted involving 22 patients with metastatic measurable bronchogenic squamous-cell carcinoma.
- Patients received ACLA-A initially at 85 mg/m2 weekly, with dose reduction to 65 mg/m2 due to severe myelosuppression.
- Sixteen patients were fully assessable for response and toxicity.
Main Results:
- Toxicity was primarily hematological, leading to dose adjustments.
- No complete or partial responses were observed in the assessable patient cohort.
- Fifteen of the 22 patients were previously untreated.
Conclusions:
- ACLA-A administered on the tested schedule lacks therapeutic efficacy for advanced bronchogenic squamous-cell carcinoma.
- Further investigation into ACLA-A for this indication is not recommended under the current treatment paradigm.